ARCHIVES

GAO: FDA Data On Drug Shortages Inadequate

This article is from The Cancer Letter archive.

Vol. 40 No. 08 | February 21, 2014

Download PDF Visit The Full Archive

Related Articles

Lung Cancer Clinical Trials Cost-Effective Alternative

October 31, 2003

DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs

December 4, 1992

Olaparib, A PARP Inhibitor, Can Reduce Tumor Size In Advanced Ovarian Cancer

August 27, 2010

FDA developing guidelines for oncology endpoints.

May 7, 2004

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012